An audit of dabigatran etexilate prescribing in Victoria

Medical Journal of Australia

Volumn 198, Issue 6, 2013, Pages 314-315

  Lim, Sueh Li A ^a   Maxwell, Ellen ^b  

^a ALFRED HOSPITAL   (Australia)

^b MELBOURNE PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN;

BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LETTER; MEDICAL AUDIT; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PRESCRIPTION;

AGED; ANTICOAGULANTS; BENZIMIDAZOLES; DRUG PRESCRIPTIONS; HUMANS; MEDICAL AUDIT; PYRIDINES; RETROSPECTIVE STUDIES; VICTORIA; WARFARIN;

EID: 84876207536     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10942     Document Type: Letter

References (5)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2. Department of Health and Ageing. Important new medicines listed on the PBS. http://www.health. gov.au/internet/ministers/publishing.nsf/Content/ mr-yr11-nr-nr196.htm (accessed Sep 2011).
3. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1286.
4. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866.
5. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.